Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vectra VAG is a veterinary pharmaceutical product, specifically a topical ectoparasiticide formulation developed for the control and prevention of flea and tick infestations in dogs. It typically contains a combination of active ingredients such as dinotefuran, pyriproxyfen, and permethrin. Dinotefuran acts as a fast-acting insecticide by binding to the nicotinic acetylcholine receptors in the insect's nervous system, leading to paralysis and death. Pyriproxyfen is an insect growth regulator (IGR) that mimics juvenile hormone, preventing the development of flea eggs and larvae into adults. Permethrin provides repellent and insecticidal activity against ticks, mosquitoes, and biting flies by disrupting sodium channel kinetics in their nerve cells. The 'VAG' designation is often associated with specific regional branding or packaging variations of the Vectra 3D line produced by Ceva Santé Animale.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vectra VAG.